Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific
Bear Case

Investors should be bearish about investing in Boston Scientific Co. for these reasons:

• A cyberattack in August 2026 disrupted manufacturing and shipping, leading the company to warn that it is unlikely to meet its previously issued third-quarter and full-year 2026 guidance for net sales and adjusted earnings per share. This operational disruption poses a significant risk to near-term financial performance and investor confidence.
• Short interest in Boston Scientific Co. has increased significantly, with 48,173,758 shares shorted as of August 31, 2026, representing a 74.4% increase from the previous month. This high level of short selling suggests that a substantial portion of the market is betting against the stock, which could lead to further price declines.
• The company faces increasing competitive pressure, as noted by Citi's recent downgrade of Boston Scientific Co. on the grounds of intensifying competition and the fallout from the cyberattack. This competitive environment may erode market share and profit margins, particularly in key areas like electrophysiology where rivals like Medtronic are gaining ground.
• Boston Scientific Co. has recently recalled its LUX Dx Cardiac Monitor due to delayed atrial fibrillation alerts. Such product recalls can damage the company's reputation, lead to regulatory scrutiny, and result in financial losses, all of which could negatively impact investor sentiment and stock performance.
• The stock has been added to the Zacks Rank #5 (Strong Sell) list, indicating that analysts expect a significant decline in earnings estimates. This negative outlook, combined with the recent guidance cut, suggests that the company may face challenges in meeting future financial targets, which could deter potential investors.